Treatment of meconium aspiration syndrome with estrogens
One aspect of the present invention relates to the use of an estrogen in the treatment of Meconium Aspiration Syndrome (MAS) in a newborn infant, said treatment comprising administering an effective amount of estrogen to said newborn infant within 7 days after birth. The present treatment offers the advantage that estrogens can be administered using non-invasive modes of administration, e.g. oral or rectal administration. Other aspects of the present invention relate to a suppository for use in newborn infants comprising at least 1 μg of estrogen and to an oral applicator comprising a container holding an aqueous liquid containing micronised estetrol and a metering dispenser for metering the liquid into the oral cavity of a newborn infant.
1. A method of treating Meconium Aspiration Syndrome (MAS) in a newborn infant, said method comprising administering an effective amount of estrogen to said newborn infant within 7 days after birth, wherein the estrogen is selected from the group consisting of estetrol, estriol, estradiol and combination thereof.
2. The method according to claim 1 , wherein the estrogen is administered within 1 day after birth.
3. The method according to claim 1 , wherein the estrogen is administered within 6 hours after birth.
4. The method according to claim 1 , wherein the estrogen is administered within 1 hour after birth.
5. The method according to claim 1 , wherein the estrogen administration is discontinued within 90 days after birth.
6. The method according to claim 1 , wherein the estrogen administration is discontinued within 30 days after birth.
7. The method according to claim 1 , wherein the estrogen is administered orally, rectally or by injection.
8. The method according to claim 7 , wherein the estrogen is administered orally or rectally.
9. The method according to claim 8 , wherein the estrogen is administered rectally.
10. The method according to claim 1 , wherein the estrogen is administered to prophylactically treat severe complications of MAS.
11. The method according to claim 1 , wherein the newborn infant exhibits symptoms of chemical pneumonia.
12. The method according to claim 1 , wherein the newborn infant is suffering from hypoxia.
13. The method according to claim 1 , wherein the estrogen is administered in an amount equivalent to an oral dosage of at least 0.1 mg estetrol.
14. The method according to claim 13 , wherein the estrogen comprises at least estetrol.